In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|October 15, 2018
MilliporeSigma Wins CPhI Pharma Award for Excellence in Innovation
Author(s)BioPharm International Editors
The company was awarded for excellence in innovation for Parteck MXP Excipient and modified amino acids.
Advertisement
On Oct. 12, 2018, MilliporeSigma announced that it won two CPhI Pharma Awards for innovative products for the pharmaceutical industry. The awards were announced at CPhI’s award gala in Madrid, Spain.
“At MilliporeSigma, we provide innovations that help our customers advance science and accelerate access to better health for people everywhere,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in a company press release. “We are pleased that CPhI has recognized our commitment to drive the industry forward and empower researchers and scientists with products that improve drug development quality and efficiency.”
The company received the following awards:
- Parteck MXP Excipient won for “Excellence in Excipients.” The product is a new polyvinyl alcohol excipient for the formulation of stable amorphous solid dispersions by hot melt extrusion. It offers enhanced API solubility and stable, high drug loads. The new excipient is applicable for a variety of final formulations with different release kinetics and offers the formulator flexibility in designing a drug product that fits the respective API and desired therapeutic effect.
- MilliporeSigma’s modified amino acids won for “Excellence in Bioprocessing and Manufacturing.” The modified amino acids Phospho-Tyrosine disodium salt and Sulfo-Cysteine sodium salt are components for biomanufacturing and mAb processes, designed to simplify fed-batch processes in applying a single-feed strategy.
The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and advocate companies that are committed to driving the industry forward. CPhI Wordwide was held in Madrid on Oct. 9–11, 2018.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5